Kala Pharmaceuticals, Inc. (KALA)
Market Cap | 18.90M |
Revenue (ttm) | n/a |
Net Income (ttm) | -39.55M |
Shares Out | 2.82M |
EPS (ttm) | -14.96 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 117,904 |
Open | 6.86 |
Previous Close | 6.89 |
Day's Range | 6.52 - 7.17 |
52-Week Range | 4.21 - 16.11 |
Beta | -1.97 |
Analysts | Strong Buy |
Price Target | 16.50 (+145.9%) |
Earnings Date | Aug 2, 2024 |
About KALA
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, I... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for KALA stock is "Strong Buy." The 12-month stock price forecast is $16.5, which is an increase of 145.90% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/d/4/conf14-2451338.jpg)
KALA BIO to Present at Jefferies Global Healthcare Conference
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative t...
![](https://cdn.snapi.dev/images/v1/s/v/press15-2430657.jpg)
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal disea...
![](https://cdn.snapi.dev/images/v1/7/q/press13-2347998.jpg)
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash res...
![](https://cdn.snapi.dev/images/v1/3/7/conf2-2293266.jpg)
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
![](https://cdn.snapi.dev/images/v1/k/i/press16-2236911.jpg)
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside ...
![](https://cdn.snapi.dev/images/v1/7/g/press2-2154352.jpg)
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with a...
![](https://cdn.snapi.dev/images/v1/q/m/conf1-2049058.jpg)
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...
![](https://cdn.snapi.dev/images/v1/9/y/press3-2007132.jpg)
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarde...
![](https://cdn.snapi.dev/images/v1/d/a/conf7-2002390.jpg)
KALA BIO to Participate in Upcoming Investor Conferences in August
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
![](https://cdn.snapi.dev/images/v1/t/y/press18-1978922.jpg)
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement aw...
![](https://cdn.snapi.dev/images/v1/j/u/conf12-1918355.jpg)
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
![](https://cdn.snapi.dev/images/v1/r/o/press5-1879131.jpg)
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 --...
![](https://cdn.snapi.dev/images/v1/l/h/press9-1860399.jpg)
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development ...
![](https://cdn.snapi.dev/images/v1/u/h/press17-1813188.jpg)
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled t...
![](https://cdn.snapi.dev/images/v1/2/j/conf14-1788259.jpg)
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization o...
![](https://cdn.snapi.dev/images/v1/1/q/press8-1781230.jpg)
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement financing, extending cash runway...
![](https://cdn.snapi.dev/images/v1/4/c/biotech33-1691322.jpg)
Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment
Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company announced positive news regar...
![](https://cdn.snapi.dev/images/v1/m/c/spying-gd714626cd-1920-1689923.jpg)
Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)
Kala Pharmaceuticals Inc KALA shares are trading higher Thursday. The stock appears to be moving on continued momentum after the company on Wednesday announced FDA acceptance of an investigational new...
![](https://cdn.snapi.dev/images/v1/b/w/biotech12-1688712.jpg)
Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment
Shares of Kala Pharmaceuticals Inc. KALA, +1.03% shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational ne...
![](https://cdn.snapi.dev/images/v1/h/e/press18-1688405.jpg)
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON...
![](https://cdn.snapi.dev/images/v1/7/t/press19-1653527.jpg)
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,...
![](https://cdn.snapi.dev/images/v1/m/s/press17-1653523.jpg)
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
![](https://cdn.snapi.dev/images/v1/r/p/press1-1624618.jpg)
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Ended Quarter with $52.4 million in Cash; Sufficie...
![](https://cdn.snapi.dev/images/v1/b/t/press15-1609944.jpg)
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, developme...
![](https://cdn.snapi.dev/images/v1/7/5/press1-1590820.jpg)
Kala Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022